new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)





Similar
Filing Names

Immatics Biotechnologies Gmbh
Immatics Biotechnologies Gmbh_20100128
  

Immatics Biotechnologies Gmbh patents

Recent patent applications related to Immatics Biotechnologies Gmbh. Immatics Biotechnologies Gmbh is listed as an Agent/Assignee. Note: Immatics Biotechnologies Gmbh may have other listings under different names/spellings. We're not affiliated with Immatics Biotechnologies Gmbh, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immatics Biotechnologies Gmbh-related inventors




Date Immatics Biotechnologies Gmbh patents (updated weekly) - BOOKMARK this page
03/02/17Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
03/02/17Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
03/02/17Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
02/09/17Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
02/09/17Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
02/09/17Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
02/09/17Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
02/09/17Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
02/09/17Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
02/09/17Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
02/09/17Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
02/09/17Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
02/09/17Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
02/09/17Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
02/02/17Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
01/26/17Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers
01/05/17Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
12/29/16Novel immunotherapy against several tumors including neuronal and brain tumors
12/29/16Novel immunotherapy against several tumors including neuronal and brain tumors
12/29/16Novel immunotherapy against several tumors including neuronal and brain tumors
12/29/16Novel immunotherapy against several tumors including neuronal and brain tumors
12/29/16Novel immunotherapy against several tumors including neuronal and brain tumors
12/29/16Novel immunotherapy against several tumors including neuronal and brain tumors
12/22/16Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
12/08/16Novel immunotherapy against several tumors including neuronal and brain tumors
12/01/16Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
12/01/16Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
11/24/16Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
10/06/16Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers
10/06/16Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers
09/29/16Novel peptides and combination of peptides for use in immunotherapy against various tumors
09/29/16Novel peptides and combination of peptides for use in immunotherapy against various tumors
09/29/16Novel peptides and combination of peptides for use in immunotherapy against various tumors
09/29/16Novel peptides and combination of peptides for use in immunotherapy against various tumors
09/29/16Novel peptides and combination of peptides for use in immunotherapy against various tumors
09/29/16Novel peptides and combination of peptides for use in immunotherapy against various tumors
09/29/16Novel peptides and combination of peptides for use in immunotherapy against various tumors
09/29/16Novel peptides and combination of peptides for use in immunotherapy against various tumors
09/29/16Novel peptides and combination of peptides for use in immunotherapy against various tumors
09/29/16Novel peptides and combination of peptides for use in immunotherapy against various tumors
09/29/16Novel peptides and combination of peptides for use in immunotherapy against various tumors
09/01/16Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
06/30/16Method for the absolute quantification of naturally processed hla-restricted cancer peptides
06/23/16Novel immunotherapy against neuronal and brain tumors
06/16/16Immunotherapy against several tumors, such as lung cancer, including nsclc
04/28/16Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
02/25/16Novel immunogenic epitopes for immunotherapy
12/24/15Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
11/12/15Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
05/28/15Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
05/07/15Personalized immunotherapy against several neuronal and brain tumors
05/07/15Novel immunotherapy against several tumors including neuronal and brain tumors
02/12/15Method for identifying immunoreactive peptides
01/22/15Combination therapy using active immunotherapy
09/18/14Novel immunogenic epitopes for immunotherapy
08/21/14Methods of using biomarkers for predicting the outcome of an immunotherapy against cancer
05/08/14Novel and powerful mhc-class ii peptides derived from survivin
03/27/14Novel and powerful mhc-class ii peptides derived from survivin
12/19/13Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
12/05/13Novel and powerful mhc-class ii peptides derived from survivin
11/21/13Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
09/26/13Method for identifying immunoreactive peptides
07/11/13Cancer therapy based on tumor associated antigens derived from cyclin d1
05/09/13Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
04/18/13Method for differentially quantifying naturally processed hla-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
Patent Packs
02/21/13Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
01/03/13Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
06/07/12Novel immunotherapy against several tumors including neuronal and brain tumors
05/24/12Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
05/03/12Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or class ii molecules for vaccines
04/05/12Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
03/22/12Use of myeloid cell biomarkers for the diagnosis of cancer
02/02/12Cancer therapy based on tumor associated antigens derived from cyclin d1
10/20/11Method for differentially quantifying naturally processed hla-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
09/22/11Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
09/22/11Methods for the diagnosis and treatment of cancer based on avl9
09/22/11Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
06/23/11Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
06/16/11Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
06/16/11Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
Patent Packs
05/19/11Novel immunogenic epitopes for immunotherapy
03/24/11Tumour-associated peptides binding to mhc molecules
01/06/11Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
07/22/10Tumour-associated peptides that bind to mhc molecules
07/22/10Tumour-associated peptides that bind to mhc molecules
06/24/10Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or class ii molecules for vaccine
06/24/10Novel immunotherapy against several tumors including neuronal and brain tumors
02/04/10Novel and powerful mhc-class ii peptides derived from survivin
02/04/10Tumor-associated peptides that bind to mhc-molecules
01/28/10Mhc molecule-binding tumor-associated peptides
12/24/09Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
01/28/10Mhc molecule-binding tumor-associated peptides







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immatics Biotechnologies Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immatics Biotechnologies Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';